Navigation Links
Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway

d other biological pathways, as well as for the development of new therapeutic candidates such as nab-docetaxel (ABI-008) and the HSP90 inhibitor nab-17-AAG (ABI 010), among others.

About nab(TM) Technology Platform

Developed by Abraxis BioScience, nanoparticle albumin-bound (nab(TM)) tumor-targeting technology harnesses the unique natural properties of the human protein albumin, to transport and deliver therapeutic agents to the site of disease. The binding of albumin to the anticancer agent creates nanometer-sized particles, which are approximately 1/100th the size of a single red blood cell. These nab particles are readily incorporated into the body's own transport processes and are able to exploit the tumors' attraction to albumin, enabling the delivery of higher concentrations of the active drug to the target site. This may lead to an increase in the drug's antitumor effect and the potential for an effective response. In addition, nab technology offers the ability to improve a drug's solubility by avoiding the need for toxic chemicals, such as solvents, in the administration process, thus potentially improving safety through the elimination of solvent-related side effects.

Abraxis BioScience received approval from the U.S. Food and Drug Administration for ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease in 2005, its first product developed using the nab technology. Studies are ongoing to evaluate several other therapeutic candidates that employ the nab technology including nab-docetaxel (ABI-008), nab-rapamycin mTOR inhibitor (ABI 009), and nab-17AAG HSP90 inhibitor (ABI 010), among others.

About Abraxis BioScience, Inc.

Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
2. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
Post Your Comments:
(Date:8/28/2015)... 28, 2015 , Joint research by ... from Biostar , Published in ,Stem Cells Translational ... lifespan through multiple IV administration of Adipose-derived MSC ... expectancy found , Commercialization within 5 years expected ... possibility that adult mesenchymal stem cells (MSCs) may extend ...
(Date:8/28/2015)... SAN FRANCISCO , August 28, 2015 ... is expected to reach USD 49.12 billion by 2020, ... 2020, according to a new report by Grand View ... an estimated CAGR of 49.7% from 2014 to 2020. ... Growing aging population along with rising incidences of ...
(Date:8/27/2015)... Aug. 27, 2015 Biosimilars are not ... the U.S. Food and Drug Administration (FDA) for ... in its draft guidance issued today. The FDA,s ... proposes distinguishable names, calling for biological products to ... suffix. This proposal reflects the agency,s thinking that ...
Breaking Medicine Technology:Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2
... Lytle LLP, one of the region,s best known law ... Court in Rochester, upheld a high-profile products liability verdict ... In its decision, the Fourth Department judicial panel found ... of Cheektowaga, NY a quadriplegic.  In making its findings, ...
... 18, 2011 The U.S. Food and Drug Administration ... (neovascular) age-related macular degeneration (AMD), a leading cause of ... older. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... affects the macula, the part of the eye that ...
Cached Medicine Technology:The Appellate Division of State Supreme Court has Upheld a Landmark 2010 Products Liability Verdict Which Found Cybex International Responsible for Catastrophic Injuries Suffered by a Cheektowaga Woman 2The Appellate Division of State Supreme Court has Upheld a Landmark 2010 Products Liability Verdict Which Found Cybex International Responsible for Catastrophic Injuries Suffered by a Cheektowaga Woman 3FDA Approves Eylea for Eye Disorder in Older People 2
(Date:8/28/2015)... ... August 28, 2015 , ... Drugs and alcohol ... Strawbridge, gives a new approach on solutions in his new book ":Unraveling The ... and employees getting together for meaningful group meetings. "This would educate the employees ...
(Date:8/28/2015)... ... August 28, 2015 , ... The ... honoring military veterans leading in business. Mr. Troy Mizell, Chairman of the ... inaugural Nashville Business Journal's 2015 Veterans Awards will recognize Nashville military veterans who, ...
(Date:8/28/2015)... ... ... Dr. Gregory K. Toumayan, D.C., Q.M.E., is now treating patients with back pain ... pain, neck pain, stiffness, muscle spasms, and numbness. , Dr. Toumayan received his ... on to earn his title of Doctor of Chiropractic from the Palmer College of ...
(Date:8/28/2015)... ... 28, 2015 , ... The Quatela Center for Plastic Surgery is excited to ... nonsurgical product approved by the Food and Drug Administration to eliminate submental fat, also ... William Koenig are among the premier cosmetic surgeons in Rochester to offer this ...
(Date:8/28/2015)... ... August 28, 2015 , ... Mendon, IL, home of the Adams County ... people, all for a good cause. In its second year, the “Music With A ... Best Drug Rehabilitation. The “Mission” of “Music With A Mission” is to raise money ...
Breaking Medicine News(10 mins):Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2
... Former NFL player and Dallas Cowboy,Jason Kaiser received top ... Kaiser earned the title of,valedictorian with a GPA of ... school and in my class especially," he said. "To ... in Parker College, Kaiser played professional football,for more than ...
... less blood loss, shorter hospital stays, study finds , , ... surgery to remove pancreatic tumors or cysts leads to ... finds. , In laparoscopic surgery, doctors make smaller ... with fiber optics and video cameras. This less invasive ...
... - QLT Inc. (NASDAQ: QLTI;,TSX: QLT) today reported financial ... specified otherwise, all amounts are in U.S. dollars,and in ... of 2008, we were pleased to report the U.S. ... for blood,monitoring from the Aczone(TM) label," said Bob Butchofsky, ...
... MAPP ) today announced that the company will,present at ... 2008:, Morgan Stanley Global Healthcare Conference, Key Biscayne, ... Time, Deutsche Bank 33rd Annual Health Care Conference, Boston, ... Time A live webcast of the presentations will be ...
... HILL, N.C., April 25 Managing multi-generational,diversity is ... recent,benchmarking study with 23 leading companies, 80 percent ... and yet only one-third say,their companies offer training ... to download an excerpt of,this new research, The ...
... Today, on World Malaria,Day, the American Red Cross is ... robust global response to this deadly disease., Each ... 300 million people, mostly children in Africa. More,than 1 ... Since 2001, the American Red Cross and its ...
Cached Medicine News:Health News:Former Dallas Cowboy Honored as Parker College of Chiropractic Top 2008 Graduate 2Health News:Former Dallas Cowboy Honored as Parker College of Chiropractic Top 2008 Graduate 3Health News:Laparoscopic Surgery on Pancreas Has Fewer Complications 2Health News:QLT announces first quarter results for 2008 2Health News:QLT announces first quarter results for 2008 3Health News:QLT announces first quarter results for 2008 4Health News:QLT announces first quarter results for 2008 5Health News:QLT announces first quarter results for 2008 6Health News:QLT announces first quarter results for 2008 7Health News:QLT announces first quarter results for 2008 8Health News:QLT announces first quarter results for 2008 9Health News:QLT announces first quarter results for 2008 10Health News:QLT announces first quarter results for 2008 11Health News:QLT announces first quarter results for 2008 12Health News:QLT announces first quarter results for 2008 13Health News:QLT announces first quarter results for 2008 14Health News:MAP Pharmaceuticals to Present at Upcoming Investor Conferences 2Health News:Multi-generational Diversity Top Challenge for Businesses Today: Leading Company to Share Insights June 4-6 2Health News:Uniting to Fight Malaria Around the World 2Health News:Uniting to Fight Malaria Around the World 3
Two prong stainless steel tips; with titanium handle/...
Straight shaft with fine pointed 0.3mm Tips for Grasping Delicate Capsule; In Titanium....
12mm from bend to 0.12mm 1x2 teeth; In Titanium....
Straight Shafts with 0.12mm 1X2 Teeth With 5mm Tying Platform; In Titanium...
Medicine Products: